Senem Karabulut

Senem Karabulut


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2019 in Biomolecules
Verified
Journal Article
Open access
PDF file
MUMuhammed zubeyr Ucuncu
Muhammed zubeyr Ucuncu
MSMurat Serilmez
Murat Serilmez
MSMurat Sarı
Murat Sarı
SBSuleyman Bademler
Suleyman Bademler
SKSenem Karabulut
Senem Karabulut
In this study, we compared the levels of C-C chemokine receptor type 5 (CCR5), C-C motif chemokine ligand 5 (CCL5), platelet-derived growth factor (PDGF), and EphrinA7 (EphA7) in patients with colorectal carcinoma and healthy controls in order to investigate the significance and usability of these potential biomarkers in early diagnosis of colorectal cancer. The study included 70 colorectal carcinoma patients and 40 healthy individuals. The CCR5, CCL5, PDGF, and EphA7 levels were measured using ELISA in blood samples. PDGF-BB, EphA7, CCR5, and CCL5 levels of the patients with colorectal carcinoma were significantly higher compared to the control group (p < 0.001 for each comparison). Our logistic regression analysis (the area under the curve was 0.958) supports the notion that PDGF-BB, EphA7, and CCL5 are potential biomarkers for the diagnosis of colon cancer. The sensitivity, specificity, and positive and negative predictive values were found to be 87.9%, 87.5%, 92.1%, and 81.4%, respectively. To our knowledge, this is the first study that investigates the relationship between colorectal carcinoma and the four biomarkers CCL5, CCR5, PDGF, and EphA7. The significantly elevated levels of all these parameters in the patient group compared to the healthy controls indicate that they can be used for the early diagnosis of colorectal carcinoma.

20 October 2013 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
SKSenem Karabulut
Senem Karabulut
FTF. Tas
F. Tas
FAF. Akyüz
F. Akyüz
AOA. C. Ormeci
A. C. Ormeci
MSM. Serilmez
M. Serilmez
VYV. Yasasever
V. Yasasever

3 June 2014 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
SKSenem Karabulut
Senem Karabulut
FTF. Tas
F. Tas
DTD. Tastekin
D. Tastekin
MKM. Karabulut
M. Karabulut
CYC. T. Yasasever
C. T. Yasasever
AAA. Aydıner
A. Aydıner

24 January 2019 in Biomolecules
Verified
Journal Article
Open access
PDF file
SBSuleyman Bademler
Suleyman Bademler
AZAlisan Zirtiloglu
Alisan Zirtiloglu
MSMurat Sarı
Murat Sarı
MUMuhammed zubeyr Ucuncu
Muhammed zubeyr Ucuncu
EDElif Bilgin Doğru
Elif Bilgin Doğru
SKSenem Karabulut
Senem Karabulut
This study was conducted to investigate the serum levels of membrane-bound mucin 2 (MUC2) in breast cancer (BC) patients and the relationship with tumour progression and known prognostic parameters. We enrolled 127 female patients with histopathologically diagnosed BC who did not receive chemotherapy (CT) or radiotherapy. Serum MUC2 levels were measured by the enzyme-linked immunosorbent assay (ELISA) method and compared with those of 40 age and sex-matched healthy controls. Median age of diagnosis was 50 (range: 26–78). Twenty-eight (22%) patients were metastatic and the most frequent site of metastasis was bone (n = 17, 61%). The median serum MUC2 level of BC patients was significantly higher than that of the controls (198 vs. 54 ng/mL, p < 0.001). There was no significant difference between patients and controls according to known disease-related clinicopathological or laboratory parameters (p > 0.05). Serum MUC2 levels were not associated with survival (p = 0.65). Although serum MUC2 levels might have a diagnostic role, their predictive and prognostic role in survival in BC patients was not detected. Serum levels of MUC2 should be investigated for diagnostic or screening purposes on a larger scale.

23 November 2013 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
SKSenem Karabulut
Senem Karabulut
DDD. Duranyıldız
D. Duranyıldız
FTF. Tas
F. Tas
UGUgur Gezer
Ugur Gezer
FAF. Akyüz
F. Akyüz
NAN. F. Aykan
N. F. Aykan

10 December 2018 in Biomolecules
Verified
Journal Article
Open access
PDF file
CACigdem Afsar
Cigdem Afsar
MKMehmet Karabulut
Mehmet Karabulut
SKSenem Karabulut
Senem Karabulut
SOSafiye Tokgoz Ozal
Safiye Tokgoz Ozal
MCMurat Cikot
Murat Cikot
FTFaruk Tas
Faruk Tas
Introduction: Pancreatic cancer (PC) is a lethal malignancy. Various diagnostic, predictive, and prognostic biomarkers have been evaluated. This study was conducted to investigate the serum levels of neural precursor cell expressed developmentally downregulated protein 9 (NEDD9) in patients with PC and the relationship between tumor progression and known prognostic parameters. Materials and Methods: Serum samples were obtained on first admission before any treatment. Serum NEDD9 levels were determined using enzyme-linked immunosorbent assay (ELISA). Age- and sex-matched healthy controls were included in the analysis. Results: In a three year period, 32 patients with a pathologically-confirmed diagnosis of PC were enrolled in this study. The median age at diagnosis was 61 years, range 38 to 84 years; the majority of the patients in the group were men (n = 20, 62.5%). The tumor was located in the head of pancreas in 21 (65.6%) patients. Forty-one percent of 17 metastatic patients who received palliative CTx (chemotherapy) were CTx-responsive. The baseline serum NEDD9 levels were significantly higher in patients with PA than in the control group (p = 0.03). Median OS of the whole group were 27 ± 7.3 weeks. Alcohol intake, performance status, and LDH levels were found to be significant prognostic factors (p = 0.006, p < 0.001, and p < 0.001, respectively). However, serum NEDD9 levels had no significantly effect on progression free survival (PFS) and overall survival (OS) (p = 0.71 and p = 0.58, respectively). Conclusions: NEDD9 is identified as a secretory biomarker for PC but it has no prognostic role.